secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2023-09-05T23:59:59+00:00
Accession:  0001601830-23-000063
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion completes Phase 1 study for REC-3964; drug well tolerated, Phase 2 planned for 2024
--------------------------------------------------------------------------------

- Phase 1 study of REC-3964 in healthy volunteers completed; no serious adverse events reported.
- 42 participants in MAD part; doses up to 900 mg for 14 days; PK dose-proportional, half-life 7-10 hrs.
- Treatment-related AEs in 11.8% (4/34) of REC-3964 recipients, all mild; no discontinuations.
- Phase 2 proof-of-concept trial in recurrent C. diff infection expected to start in 2024.
- REC-3964 is novel non-antibiotic small molecule inhibitor of C. diff toxins; >730k cases US/EU5 annually.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183023000063/0001601830-23-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183023000063/rxrx-20230905.htm
  HTML page:      https://secwatch.observer/filing/0001601830-23-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer